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Abstract
Background Despite regulatory efforts to formalize guid-
ance policies on biosimilars, there remains a need to edu-
cate healthcare stakeholders on the acknowledged
definition of biosimilarity and the data that underpin it.
Objectives The objectives of the study were to systemati-
cally collate published data for monoclonal antibodies and
fusion protein biosimilars indicated for cancer, chronic
inflammatory diseases, and other indications, and to
explore differences in the type and weight (quantity and
quality) of available evidence.
Methods MEDLINE, Embase, and ISI Web of Science
were searched to September 2015. Conference proceedings
(n = 17) were searched 2012 to July 2015. Included
studies were categorized by originator, study type, and
indication. To assess data strength and validity, risk of bias
assessments were undertaken.
Results Across therapeutic areas, 43 named (marketed or
proposed) biosimilars were identified for adalimumab,
abciximab, bevacizumab, etanercept, infliximab, omal-
izumab, ranibizumab, rituximab, and trastuzumab origina-
tors. Infliximab CT-P13, SB2, and etanercept SB4
biosimilars have the greatest amount of published evidence
of similarity with their originators, based on results of
clinical studies involving larger numbers of patients or
healthy subjects (N = 1405, 743, and 734, respectively).
Published data were also retrieved for marketed intended
copies of etanercept and rituximab.
Conclusions This unbiased synthesis of the literature
exposed significant differences in the extent of published
evidence between molecules at preclinical, clinical, and
post-marketing stages of development, providing clinicians
and payers with a consolidated view of the available data
and remaining gaps.
Key Points
The quantity and quality of published preclinical and
clinical data for approved or proposed biosimilars
and intended copies varies widely.
This synthesis of available evidence provides an
unbiased resource to inform and support clinical
decision making.
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The arrival of biosimilars for a number of key recombinant
biologics, including the first approved monoclonal anti-
bodies (mAbs) [1–3], is expected to provide cost savings to
healthcare systems and offers the potential to expand
patient access to important medicines [4, 5]. Outside of the
EU or the USA, experience of the regulatory pathway
leading to approval of mAb or fusion protein biosimilars by
major health authorities remains limited. Nevertheless,
regulatory environments across all markets are evolving
rapidly, with extensive global industrial biologic develop-
ment and manufacturing experience [6, 7], accompanied by
rising standards of clinical care. Over the past few years,
there has also been a steady increase in the body of evi-
dence—in the form of robust peer-reviewed publications
available in the public domain—for biosimilars on the
market and in development.
CT-P13 (RemsimaTM/InflectraTM; Celltrion, South
Korea/Hospira, USA) was the first EU-approved mAb
infliximab biosimilar, obtaining market authorization in
September 2013, across all approved indications of Remi-
cade for rheumatoid arthritis (RA), Crohn’s disease,
ulcerative colitis, ankylosing spondylitis, psoriatic arthritis,
and psoriasis [8, 9]. In May 2016, SB2 (Flixabi; Samsung
Bioepis), an infliximab biosimilar, was also approved in the
EU for the treatment of adults with RA, Crohn’s disease,
ulcerative colitis, ankylosing spondylitis, psoriatic arthritis,
and psoriasis [10]. In January 2016, SB4 (Benepali; Bio-
gen, Samsung Bioepis, South Korea) became the first etan-
ercept biosimilar to Enbrel to be approved in the EU for the
treatment of adults with moderate to severe RA, psoriatic
arthritis, non-radiographic axial spondyloarthritis, and pla-
que psoriasis [11]. Marketing authorization applications for
ABP 501 (adalimumab; Amgen) and GP2015 (etanercept;
Sandoz, Switzerland) were submitted to the European
Medicines Agency (EMA) in 2015 [12–14] and were still
undergoing evaluation at the time of writing this article.
In the USA, the FDA guidance documents on scientific
and quality considerations in the demonstration of
biosimilarity were finalized in April 2015 [15]. Almost
1 year later, the FDA released draft guidance for industry
on the labeling of biosimilar products, which provides an
overview of the FDA’s recommendations for biosimilar
labels and is intended to support the development of draft
labeling for submission in proposed biosimilar product
applications [16, 17]. In April 2016, the FDA approved the
infliximab biosimilar, CT-P13 for multiple indications
[18]. CT-P13 is the first mAb biosimilar to be approved in
the USA and only the second biosimilar to be granted FDA
approval [18, 19]. In July 2016, the FDA Arthritis Advi-
sory Committee unanimously voted to recommend
approval of Sandoz’s etanercept biosimilar, GP2015 [20].
Also in July 2016, the FDA advisory panel voted in favor
of recommending approval for ABP 501, Amgen’s pro-
posed biosimilar of adalimumab [21].
Biosimilars are thus required to meet rigorous regulatory
standards on biosimilarity and, as such, the term ‘biosim-
ilars’ is applied to products that meet these standards. In
contrast, the terms ‘intended copies’ or ‘non-comparable
biologics’ are applied to products that have not undergone
rigorous similarity exercises but are marketed nevertheless
[1, 22, 23]. The published data available on these products
are insufficient to provide robust evidence compared with
the originator product [24].
Despite regulatory efforts across major markets to for-
malize guidance policies on biosimilars, there remains an
ongoing need to inform and educate healthcare profes-
sionals and payers on the acknowledged definition of
biosimilarity and to keep stakeholders abreast of any
developments regarding the labeling, substitution, and
indication extrapolation of biosimilar candidates. Payers
and clinicians would benefit from more information on the
weight and breadth of evidence available for proposed or
approved biosimilars to support more informed prescribing
and coverage decisions.
Currently, no published reviews are available that have
systematically summarized all of the available studies on
biosimilars across all stages of development and across
multiple therapeutic areas. With these considerations in
mind, a comprehensive literature review was undertaken to
identify, collate, and summarize published empirical evi-
dence on proposed or approved mAb and fusion protein
biosimilars indicated for cancer, chronic inflammatory dis-
eases, and other indications. The intent of this researchwas to
provide a robust overview of biosimilar molecules currently
in development, in human clinical trials, or on the market,
and to explore differences in the type andweight of evidence.
The results presented in this study represent findings from the
published literature (up to the analysis cut-off date for this
article, 3 September 2015) and provide insight on the dataset
available for these classes of biosimilars. The authors also
reviewed planned, ongoing, or completed trials with cur-
rently unpublished data (up to the analysis cut-off date for
this article, 21 September 2015).
This work is intended to provide an introduction to the
field of biosimilars and reports on the methodology and
high-level findings of the systematic literature review
(SLR). A detailed analysis of the full study data and
remaining knowledge gaps for each therapeutic area will be
presented in a series of follow-on manuscripts currently in
development and will include all reported outcomes across
the identified empirical study types, quality assessment
results, and a thematic analysis of the retrieved non-em-
pirical publications.
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2 Methods
2.1 Systematic Literature Review
The MEDLINE/Medline in process and Embase electronic
databases were searched using the OVIDSP interface from
database inception to 3 September 2015. The ISI Web of
Science database was searched up to 3 September 2015.
The search strategy was executed on 27 April 2015 and
was refreshed on 3 September 2015 to capture recent full-
text publications. First, search terms were used that capture
‘mAb’, ‘fusion protein’, or ‘interleukin-1 receptor-antago-
nist’ terms. Second, search terms were used that encompass
the different terminologies for biosimilar products,
including, for example, ‘biosimilars’, ‘subsequent entry
biologics’, ‘follow-on biologics’, ‘follow-on proteins’,
‘biocomparables’, ‘biogenerics’, ‘similar biotherapeutic
products’, and ‘intended copies’ or ‘biobetters’ (which
were analyzed separately). Controlled vocabulary and free-
text terms were used, and the search results were filtered
using the study designs of interest. The final search result
from each database was limited to references published in
the English language. Included publications were required
to contain both a ‘mAbs/fusion protein’ term and a
‘biosimilars’ term. To capture the latest studies not yet
published as full-text articles and/or supplement results of
previously published studies, a hand-search of key con-
ference proceedings (n = 17) was conducted for the period
of 1 January 2012 to 31 July 2015. The complete list of
conference proceedings can be found in Table S1 in the
Electronic Supplementary Material (ESM) and includes
disease-specific (i.e., for oncology or chronic inflammatory
disease), health economics and outcomes research, regu-
latory/payer-focused, and manufacturing/development-
themed meetings that were prioritized on the basis of the
quantity and quality of biosimilar content in 2014. Searches
were also conducted using the US National Library of
Medicine (NLM) ClinicalTrials.gov registry to identify
biosimilars in development that did not appear in the
published literature or in the identified congresses. Hand-
screening was used to identify relevant records due to the
limited extent of the searches available for
ClinicalTrials.gov.
2.2 Eligibility Criteria
All publication types with a ‘biosimilar’ and either a ‘mAb’
and/or ‘fusion protein’ term were included, with the
exception of case studies/case reports, short news reports,
or congress overviews. The publication types of interest
were empirical publications of studies (i.e., analytical,
functional, or nonclinical [collectively referred to as
preclinical]), clinical (i.e., pharmacokinetics [PK]/safety
trials in healthy subjects or patients and comparative
safety/efficacy trials), observational (prospective, retro-
spective, and post-marketing), and non-empirical publica-
tions including publications reporting manufacturing or
supply topics and themes, review articles, opinion pieces or
commentaries, regulatory/policy-related content and pub-
lished descriptions of product-related patient support pro-
grams, and any other non-empirical publication type
relevant to biosimilars meeting the inclusion criteria.
2.3 Study Categorization
A stepwise approach was undertaken to categorize publi-
cations by biosimilar molecule, indication, reference pro-
duct, and study type (ESM Table S2). Two independent
reviewers separated empirical publications disclosing
‘candidate development’ or brand names of biosimilars
(collectively referred to as ‘named biosimilars’ hereafter)
from non-empirical publications and from those that did
not disclose the name of a biosimilar. For the empirical
studies, one reviewer extracted information regarding the
reference biologic (where available), the named biosimilar,
indication, study type, study characteristics, study out-
comes, and parameters assessed. A blinded second
reviewer classified a 10% sample of these; in the event of
finding a 5% discrepancy, the database was re-evaluated.
Any discrepancies were resolved by consensus among
reviewers. A similar approach was taken for categorization
of non-empirical publications.
In this analysis, biosimilars are differentiated from
marketed ‘intended copies’ based on whether they meet the
established rigorous regulatory requirements for biosimi-
larity as outlined by major regulatory health authorities
such as the EMA, FDA, Health Canada, Pharmaceuticals
Medical Devices Agency/Japan Ministry for Health Labour
and Welfare (PMDA/MHLW), or the Korean Ministry of
Food and Drug Safety (MFDS). Unless identified as an
approved biosimilar or a marketed intended copy, all
molecules presented in this review are considered devel-
opment candidates (or ‘proposed biosimilars’), with final
determination of their status pending.
2.4 Risk of Bias Assessment
A risk of bias assessment was undertaken for each indi-
vidual study using a validated tool matched to study type to
assess the strength/validity of the empirical data in accor-
dance with the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) guidelines [25, 26].
An assessment of the quality for the reporting of random-
ized controlled trials (RCTs) was carried out using
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recommendations from the UK National Institute for
Health and Care Excellence (NICE) single technology
appraisal (STA) manufacturer’s template [27]. In addition,
the Jadad scoring system was used for all included RCTs
[28]. The quality of all included non-randomized/obser-
vational studies was assessed using the Downs and Black
instrument [29]. As abstracts from conference proceedings
report limited information on studies, the Downs and Black
instrument was modified to include only the 12 most crit-
ical qualifying parameters (of 26) for quality assessment.
Detailed parameters related to process were excluded as
these data were not available in abstract formats, e.g.,
suitability of statistical method employed. Animal studies
were assessed using the SYRCLE’s Risk of Bias tool [30],
and pharmacoeconomic studies were evaluated using
Drummond’s checklist for assessing economic evaluations
[31].
3 Results
3.1 Literature and Conference Search
Results of the systematic search and screening of the
biosimilars literature are presented in a PRISMA diagram
[32, 33] for the empirical studies, with a separate desig-
nation in the diagram for non-empirical publications (e.g.,
commentaries, reviews, manufacturing/supply topics)
(Fig. 1).
The search strategy yielded 1991 publications from
the title and abstract screen, and those relevant to the
topic of biosimilars (as defined by our criteria) were
retained (768 publications in total). Of the 768 included
publications, 244 (32%) were identified as empirical
publications, 491 (64%) were non-empirical publications
(i.e., review or opinion articles), and 33 (4%) corre-
sponded to payer or healthcare professional surveys. The
number of publications is higher than the number of
studies, as some studies were disseminated in more than
one publication (Fig. 1).
The number of publications included in the analysis are
presented in Fig. 2. Of the included references, 147 (19%)
reported mAb or fusion protein biosimilars for use in
oncology and 301 (39%) addressed biosimilars for the
treatment of chronic inflammatory conditions. A total of 12
(2%) publications were classified as ‘other’, and a further
465 (61%) could not be classified by indication and were
categorized as ‘not specified’. A degree of overlap in the
reported indications was also noted. For example, ritux-
imab biosimilar publications were reported for both the
oncology and inflammatory disorders categories, where
relevant, as rituximab is indicated for both therapeutic
areas.
3.1.1 Empirical Publications
Of the identified 244 empirical publications (and prior to
data extraction), 64 (26%) were classified as analytical, 55
(23%) as nonclinical, and five (2%) as ‘other’. In total, 83
publications (34%) reported RCTs, and 31 (13%) were
classified within the observational/post-marketing cate-
gory; 13 (5%) were relevant to health economics and seven
reported both nonclinical and human clinical studies
(Fig. 2). Since a handful of references included both non-
clinical and human clinical data and were reported in more
than one category, the publication counts do not sum to
totals. Named biosimilars were identified in 90 unique
studies (reported across 148 publications); 23 studies were
reported in 36 publications in oncology, 55 studies (96
publications) in chronic inflammatory disease, ten studies
(14 publications) in oncology and inflammatory diseases,
and two studies (two publications) in ‘other’ diseases.
3.1.2 Non-Empirical Publications
Of the total number of included publications, 491 were
categorized as non-empirical, of which 176 (36%) were
overview articles, 139 (28%) covered regulatory issues
and/or safety, 109 (22%) were regarding development and
production, and 54 (11%) were related to market analysis
and uptake and 13 (3%) review or opinion articles covered
other topics that were not classified (Fig. 2).
Within the overview category, the most common publi-
cations were ‘general’ overview articles (n = 83 [17%]),
and a further 74 publications provided an overview of a given
therapy area (n = 74 [15%]). The majority of publications
on regulation and safetywere concernedwith regulatory and/
or policy topics (n = 121 [25%]). Among the publications
concerning development and production, most focused on
biosimilar development (n = 42 [9%]) or quality or analysis
methods (n = 43 [9%]). Market analysis and/or commercial
uptake articles were predominantly concerned with eco-
nomics or pricing (n = 21 [4%]) (Fig. 2).
3.2 Named Biosimilars of Monoclonal Antibody
(mAb) and Fusion Protein Originators Across
Therapy Areas
3.2.1 Overview of Biosimilars in Development: Key
Manufacturers
In total, 21 different mAb or fusion protein originators
were identified relevant to the topic of biosimilars (ESM
Table S3). Figure 3 shows the number of molecules
reported to be in development for each manufacturer
classified by originator and therapy area. Across therapy
areas, named biosimilars were reported for the following
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nine identified originators: adalimumab, abciximab, beva-
cizumab, etanercept, infliximab, omalizumab, ranibizumab,
rituximab, and trastuzumab. Marketed intended copies
were identified for etanercept and rituximab. In total, 43
named biosimilars (and a further four marketed intended
copies) were identified from 27 different manufacturer/
development partnerships (Fig. 3).
3.2.2 Biosimilars in Oncology
For bevacizumab, four proposed biosimilars (ABP 215
[Amgen/Allergan], BCD-021 [Biocad], PF-06439535 [Pfi-
zer], and RPH-001 [Alphamab]) were identified in empir-
ical and non-empirical publications, of which ABP 215 was
cited the most frequently, in two empirical studies reported
across four publications. The following proposed trastu-
zumab biosimilars were reported: BCD-022 (Biocad), CT-
P6 (Celltrion/Hospira), FTMB/ABP 980 (Amgen/Synthon/
Allergan), and PF-05280014 (Pfizer), of which
PF-05280014 was referenced the most frequently, in five
empirical studies reported across 11 publications. Although
the originator mAb cetuximab was referenced in empirical
and non-empirical publications (n = 7 and n = 2, respec-
tively), no named biosimilars were identified in these
reports. Publications that did not disclose unique names of
biosimilars were categorized as ‘biosimilars without
unique identifiers’ (ESM Table S3).
3.2.3 Biosimilars in Chronic Inflammatory Diseases
Within the chronic inflammatory disease category, 14 differ-
ent mAb or fusion protein originators were identified from the
retrieved biosimilar publications. Named biosimilars were
found for originators adalimumab, etanercept, and infliximab.
For adalimumab, five proposed biosimilars were found: ABP
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excluded (1223)
Fig. 1 PRISMA flow diagram
showing the high-level
breakdown of the publication
counts. Where duplicates were
retrieved for studies, originals
(first published article) were
retained if no additional data
were provided in encore
publications. If new data were
identified, subsequent
publications were included
together with the original
publication. This affected
overall publication count but not
overall study count. Note: Of
the total 244 empirical
publications, 90 empirical
studies of named biosimilars or
intended copies were identified,
reported across 148 publications
(23 studies in 36 publications in
oncology, 55 studies in 96
publications in chronic
inflammatory diseases, ten
studies in 14 publications in
oncology and chronic
inflammatory diseases, two
studies in two publications in
‘other’ diseases) and 96
empirical publications did not
name the biosimilar being
evaluated
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non-empirical publication types.
Note: Publications were
classified into the most relevant
category, which in some cases
was more than one. Therefore,
the number of publications
classified into each therapeutic
area category does not sum to
the total number of publications.
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Celltrion (South Korea)/Hospira (USA)
Center of Molecular Immunology (Cuba)
Coherus Biosciences, Inc. (USA)
Coherus Biosciences, Inc. (USA)/Daiicho Sankyo (Japan)/Baxalta (USA)
Dr Reddy's Laboratories (India)
Hanwha Chemical (South Korea)/Merck (USA)
ISU ABXIS (South Korea)
LG Life Sciences (South Korea)
mAbxience (Switzerland)
mAbxience (Switzerland)/Laboratorio Elea S.A.C.I.F. y A. (Argentina)/LIBBS (Brazil)
Mycenax Biotech/TSH Biopharm Corp (Taiwan)




Ranbaxy Laboratories (India)/Epirus Biopharmaceuticals (USA)
Samsung (South Korea) 
Samsung Bioepis (South Korea)
Sandoz (Switzerland)
Shanghai CP Guojian Pharmaceutical (China)
Omalizumab (other disease area) Ranibizumab (other disease area)
Fig. 3 Biosimilar development pipeline: key manufacturers, country, and number of biosimilar agents categorized by originator and therapy
area. Includes manufacturers with marketed intended copies (individual products indicated by an asterisk on the bar)
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(ExemptiaTM; Cadila Healthcare), GP2017 (Sandoz),
PF-06410293 (Pfizer), and SB5 (Samsung Bioepis). ABP 501
was reported in four empirical studies, which were reported in
seven empirical publications. GP2017 was evaluated in two
studies, which were reported in three separate empirical
publications. Four biosimilars were identified for infliximab:
BOW015; (Ranbaxy Laboratories/Epirus Biopharmaceuti-
cals; development now suspended), CT-P13 (EMA/FDA
approved), PF-06438179 (Pfizer), and SB2 (EMA approved).
Of these infliximab biosimilars, approved biosimilar CT-P13
was reported by far themost frequently (in 20 studies reported
in 38 empirical publications and in 38 non-empirical
publications). The following six biosimilars were identified
for etanercept fusion protein: AVG01 (Avesthagen), ENIA11
(TuNEX; Mycenax Biotech/TSHBiopharm Corp), GP2015
(recommended for FDA approval), HD203 (Hanwha Chem-
ical/Merck), LBEC0101 (LG Life Sciences), and SB4 (EMA
approved) (ESM Table S3).
3.2.4 Biosimilars in Both Oncology and Chronic
Inflammatory Diseases
Rituximab was identified in empirical and non-empirical
publications (for either cancer or inflammatory conditions
Table 1 Biologic originator rituximab and corresponding named biosimilar agents in oncology and inflammatory disease classified by empirical
study typea







1B8 (Center of Molecular Immunology, Cuba)
Onc: [113]





BCD-020 (AcellBiaTM; Biocad, Russia)
Onc: [38, 114, 115]
Onc: 3 (1)
–
– – – – –




– – – – –
GP2013 (Sandoz, Switzerland)d
Onc: [49, 117–119]
Inflamm: [49, 117, 119]







Inflamm: [51, 67, 120–127]
–
Inflamm: 5 (1)















SAIT101 (Samsung BioLogics, South Korea)d [44] Onc: 1 (1) – – – – –
IC of rituximab










RedituxTM (IC) (Dr. Reddy’s Laboratories, India)d
Onc: [36, 37, 39, 46, 90, 129–133]
Inflamm: [39, 62, 65, 90, 129–131, 134]







Biosimilars without unique identifiers – 3 3 6 – 1
Corresponding indications for study counts for rituximab are labelled with ‘Onc’ for oncology and ‘Inflamm’ for chronic inflammatory disease
IC intended copy, mAbs monoclonal antibodies, RCT randomized controlled trial
a Italic font indicates biosimilars that are included in at least one reference naming multiple biosimilars
b Alternative names for biosimilars are provided where applicable
c Reference counts correspond to the number of identified publications. The number of unique empirical studies reported for named biosimilars
is shown in parentheses
d Several studies/publications were classified under both oncology and inflammatory disease indications or the disease area was not specified
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or, in some cases, for combined indications). Among the
rituximab biosimilar publications, seven proposed biosim-
ilars were referenced (the majority in empirical publica-
tions): 1B8 (Center of Molecular Immunology, Cuba),
BCD-020 (Biocad), CT-P10 (Celltrion/Hospira), GP2013
(Sandoz), PF-05280586 (Pfizer), RTXM83 (mAbxience),
and SAIT101 (Samsung BioLogics). For the proposed
biosimilars of rituximab, PF-05280586 was most often
reported (ESM Table S3), with published data available for
two oncology studies (four publications) and five chronic
inflammatory disease studies (ten publications).
3.2.5 Biosimilars in Other Disease Areas
Within the ‘other’ disease area category (including car-
diovascular disorders, respiratory [allergic] conditions, and
eye conditions), three proposed biosimilars, clotinab (ISU
ABXIS), CMAB007 (National Engineering Research
Center of Antibody Medicine), and PF582 (Pfenex/Hos-
pira), were identified for abciximab (cardiovascular),
omalizumab (respiratory/asthma), and ranibizumab (oph-
thalmology), respectively. Clotinab and CMAB007 were
each reported in one empirical study, and PF582 was
reported once in a non-empirical publication (ESM
Table S3).
3.3 Empirical Publications in Oncology
The reference counts for empirical studies and publications
for identified originators in oncology, along with corre-
sponding proposed biosimilars, are shown in Fig. 4. As
rituximab is licensed for oncology and chronic inflamma-
tory conditions, the analyses are presented separately. Pfi-
zer’s PF-05280014 (trastuzumab) was the most commonly
reported proposed biosimilar in oncology (Fig. 4), reported
in seven RCT publications (for three unique RCT studies),
five nonclinical publications (covering two unique studies),
and four analytical publications (describing two unique
studies). The second most frequently reported biosimilar
was ABP 215, a proposed bevacizumab biosimilar, iden-
tified in two RCT publications (one study), four nonclinical
publications (two studies), and one analytical publication
describing a single study.
At study cut-off, all biosimilars except RPH-001
(Alphamab, China/R-Pharm, Russia) and PF-06439535
had entered into clinical stages of development, with
published RCT data available in at least one study.
Interestingly, despite entering into clinical development
programs, published analytical and nonclinical data were





































RCT studies Nonclincal studies Analytical studies RCT publications Nonclinical publications Analytical publications
Bevacizumab
Trastuzumab
Fig. 4 Frequency of reported named biosimilars in oncology. Excludes data (shown in Table 1) on biosimilars or intended copies of rituximab.
RCT randomized controlled trial
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3.4 Empirical Publications in Chronic
Inflammatory Diseases
The reference counts for empirical studies and publications
for identified originators in chronic inflammatory disease,
along with corresponding biosimilars, are shown in Fig. 5.
Of the biosimilars indicated for chronic inflammatory
conditions (namely biosimilars of adalimumab, etanercept,
and infliximab), Celltrion’s CT-P13 was the most com-
monly reported, across all stages of development.
A total of 18 RCT publications (reporting three unique
RCT studies) and ten observational/post-marketing publi-
cations (eight studies) were identified for CT-P13. During
the study period, CT-P13 was evaluated in one nonclinical
study, three analytical studies, and in six health economic
studies. Several proposed biosimilars for chronic inflam-
matory diseases (namely SB5, ENIA11, and LBEC101 (LG
Life Sciences, South Korea); etanercept) had entered into
clinical development stages with published PK/safety data
in healthy subjects, without published data from preclinical
(analytical, functional, or nonclinical) studies. Further-
more, ZRC-3197, HD203, SB4, BOW015, and SB2 all had
published data from PK/safety studies and/or comparative
safety/efficacy trials (in RA), without underlying published
data or evidence to suggest that they demonstrate similar
structural or functional resemblance to that of their
originators.
3.5 Empirical Publications on Biosimilars
of Rituximab for Both Oncology
and Inflammatory Diseases
PF-05280586 was the highest reported molecule, in five
RCT publications (one study), six nonclinical publications
(two studies applicable to the oncology indication and three
studies applicable to inflammatory disease), and five ana-
lytical publications (two studies applicable in both therapy
areas) (Table 1). BCD-020, RTXM83, and SAIT101 have
all been evaluated in RCTs for oncology only, with pub-
lished data available for just one RCT each to date. For
RCTs in chronic inflammatory disease, CT-P10 and
PF-05280586 have both been evaluated in a single study.
Of the seven identified rituximab biosimilars, only four
(namely, 1B8, GP2013, PF-05280586, and RTXM83) had
undergone head-to-head analytical and nonclinical assess-
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Fig. 5 Frequency of reported named biosimilars and intended copies in chronic inflammatory diseases. IC intended copy, RCT randomized
controlled trial
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analytical data, upon meeting the scientific rigors of simi-
larity assessment outlined by the EMA and FDA, can be
used to extrapolate to either oncology or chronic inflam-
matory disease indications.
3.6 Empirical Publications in Other Disease Areas
Only three proposed biosimilars were identified in this
category: clotinab, a biosimilar of abciximab (for cardio-
vascular disorders); CMAB007, a biosimilar of omal-
izumab (for respiratory conditions); and PF582, a
ranibizumab biosimilar for ophthalmologic conditions
(Table 2).
Generally, published empirical studies for biosimilars in
other disease areas are scarce. To date, very little RCT or
preclinical data have been published to support the use of
these proposed biosimilars for these indications. Two
empirical studies (both clinical PK/safety investigations),
were identified for CMAB007 and clotinab.
3.7 Published or Ongoing Comparative Clinical
Studies
Since demonstration of biosimilarity for FDA or EMA
approval requires rigorous comparison with the originator
molecule, the majority of the identified empirical studies
compared some aspect of a biosimilar with its originator
molecule—a finding that was apparent across all study
types and in all therapy areas. A number of studies have
also compared the biosimilar of interest with the originator
from both US and EU sources across oncology and chronic
inflammatory disease areas. To facilitate comparisons
across molecules and to highlight gaps in the evidence
base, Table 3 presents a summary of all of the comparative,
PK/safety, safety/efficacy, and post-marketing/observa-
tional studies identified for each molecule.
Within oncology, all of the identified proposed biosim-
ilars with the exception of RPH-001 (Alphamab/R-Pharm)
were either undergoing or had completed comparative PK/
safety studies or comparative efficacy/safety trials versus
bevacizumab at the time of analysis.
For the proposed trastuzumab biosimilars (BCD-022,
CT-P6, FTMB/ABP 980, PF-05280014, and SB3 [Sam-
sung Bioepis]), a number of comparative PK/safety or
safety/efficacy trials were either ongoing or complete
with published data versus trastuzumab at the time of
analysis.
For the rituximab biosimilars being investigated within
oncology, published comparative data from PK/safety or
safety/efficacy trials versus rituximab were reported for
RTXM83, SAIT101, and BCD-020, respectively. At the
time of review, ongoing comparative safety/efficacy trials
were reportedly also underway for BCD-020, CT-P10,
GP2013, PF-05280586, and RTXM83.
In chronic inflammatory diseases, a number of com-
parative safety/efficacy trials for the rituximab biosimilars
BCD-020, BI 69550 (Boehringer Ingelheim), and CT-P10
were reported as ongoing (but without published data at the
time of analysis). Published comparative PK/safety trials in
patients with RA were published for CT-P10 and
PF-05280586.
Among the adalimumab, etanercept, and infliximab
biosimilars, efficacy/safety data in RA versus the originator
were published for ZRC-3197, HD203, SB4, BOW015,
CT-P13, and SB2.
Comparative safety/efficacy trials were reportedly
ongoing (with no publications to date) for a number of
adalimumab biosimilars in chronic inflammatory diseases
(Table 3). Comparative PK/safety evaluations were also
reportedly underway for adalimumab biosimilars BCD-057
(Biocad), LBAL (LG Life Sciences), PF-06410293, and
SB5 at the time of analysis.
Table 2 Originator monoclonal antibodies and corresponding named biosimilar agents in other disease areas classified by empirical study type
Biologic
originatora






Abciximab Clotinab (ISU ABXIS) [88] 1 (1) – – – – –
Omalizumab CMAB007 (National Engineering Research Center
of Antibody Medicine, China) [89]
1 (1) – – – – –
Ranibizumab PF582 (Pfenex, USA/Hospira, USA) – – – – – –
mAbs monoclonal antibodies, RCT randomized controlled trial
a Abciximab is indicated for cardiovascular disorders, omalizumab is indicated for respiratory (allergic) conditions, ranibizumab is indicated for
eye conditions (ophthalmology)
b Alternative names for biosimilars are provided where applicable
c Reference counts correspond to the number of identified publications. The number of unique empirical studies identified is indicated in
parentheses
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The etanercept biosimilars ENIA11, HD203,
LBEC0101, and SB4 all had published comparative PK/
safety data. Comparative efficacy/safety studies were
reported as still active or completed for CHS-0214 (Co-
herus Biosciences/Daiicho Sankyo/Baxalta), ENIA11 (vs.
disease-modifying anti-rheumatic diseases [DMARDs]),
GP2015, and LBEC0101.
Among infliximab biosimilars, comparative efficacy/
safety trials were reported as ongoing for CT-P13 and
PF-06438179. A comparative PK/safety trial of BCD-055
(Biocad) in ankylosing spondylitis was also identified in
the search of ClinicalTrials.gov. At the time of the review,
no published data had been retrieved for BCD-055.
Unsurprisingly, at the analysis cut-off, approved
biosimilar CT-P13 had the greatest number of published
studies (one clinical PK/safety, two clinical safety/effi-
cacy), with a further study (clinical safety/efficacy) listed
in ClinicalTrials.gov but not published at the time of
review.
The findings additionally demonstrate a significant body
of past or ongoing clinical trial activity for biosimilars in
development across both oncology and chronic inflamma-
tory disease areas, particularly for trastuzumab biosimilars
CT-P6 and PF-05280014 and for adalimumab biosimilars
ABP 501 and PF-06410293, respectively.
A detailed evaluation of the findings across all of these
studies will be presented as part of a separate analysis of
biosimilars for the treatment of chronic inflammatory dis-
eases and cancer (Jacobs et al. 2016b [submitted]; Jacobs
et al. 2016c [manuscript in preparation]).
3.8 Intended Copies
Empirical data on marketed intended copies of etanercept
(Yisaipu [Etanar; Shanghai CP Guojian Pharmaceuti-
cal], Infinitam [Probiomed]) and rituximab (Kikuzubam
[Probiomed], RedituxTM [Dr. Reddy’s Laboratories]) were
identified in the published literature (Table 1; Fig. 5; ESM
Table S3).
Yisaipu was reported in four studies described in four
empirical publications (Fig. 5; ESM Table S3). Infinitam
was investigated in two studies reported in two publica-
tions (Fig. 5; ESM Table S3).
Kikuzubam was reported in a single study in oncology
(one publication) and in two independent studies (two
publications) in chronic inflammatory disease (Table 1;
ESM Table S3). RedituxTM was referenced in eight
oncology studies (in ten publications) and seven inflam-
matory disease studies (in eight publications) (Table 1;
ESM Table S3).
In summary, most comparative studies reported for
intended copies were either analytical/nonclinical or
observational in nature, with only a single RCT identified
for Infinitam (Table 3). Suffice to say, significant evi-
dence gaps remain with respect to the efficacy and safety of
intended copies for the treatment of cancer and chronic
inflammatory diseases based on the published information
currently available.
3.9 Risk of Bias Assessments for Empirical Studies
3.9.1 Oncology Studies
Two RCTs [34, 35] were evaluated using the NICE STA
template and Jadad scoring tool (ESM Fig. S1). Both
studies were considered excellent quality. Two observa-
tional studies [36, 37] were assessed using the Downs and
Black scoring tool (ESM Fig. S2). Both were considered
good quality. Since abstracts generally provide limited
information on study methodologies and outcomes, the
Downs and Black instrument was adapted to assess the
quality of the 11 identified abstracts for original studies
[38–48]. The total score was fair quality (3–4) for one
study [39], good quality (5–8) for two studies [41, 46], and
excellent quality (9–12) for eight studies
[38, 40, 42–45, 47, 48] (ESM Fig. S3). The majority of
studies published as conference abstracts were of good or
excellent quality (90.9%). Three animal studies were
assessed using SYRCLE’s risk of bias tool [49–51] (ESM
Fig. S4) and found to be of moderate quality. Nonclinical
abstract publications and cell-based or analytical studies
were not assessed for risk of bias, as validated risk of bias
assessment tools for these types of studies and publications
were unavailable at the time of analysis.
3.9.2 Chronic Inflammatory Disease Studies
Seven RCTs were assessed using the NICE STA manu-
facturer’s template and Jadad scoring tool [52–58], and all
were considered excellent quality (ESM Fig. S1). Four
observational studies were assessed using the Downs and
Black scoring tool [59–62] and considered to be of fair
quality (ESM Fig. S2). The modified Downs and Black
instrument was used to assess the quality of the 22 iden-
tified abstracts for original studies [39, 63–83], with scores
of fair quality (3–4) for four studies [39, 66, 70, 76], good
quality (5–8) for seven studies [63, 65, 67, 68, 73, 77, 79],
and excellent quality (9–12) for 11 studies
[64, 69, 71, 72, 74, 75, 78, 80–83] (ESM Fig. S3). The
majority of studies published as conference abstracts were
of good or excellent quality (81.8%). Three animal studies
were assessed using SYRCLE’s risk of bias tools
[49, 51, 84] and found to be of moderate quality (ESM
Fig. S4). Three health economic studies were assessed
using Drummond’s checklist for assessing economic
evaluations [85–87] and considered good quality (ESM
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Fig. S5). As with studies identified for oncology, nonclin-
ical abstract publications and cell-based or analytical
studies were not assessed for risk of bias.
3.9.3 Other Disease Area Studies
Two RCTs were assessed using the NICE STA manufac-
turer’s template and Jadad scoring tool [88, 89]; both were
considered good quality (ESM Fig. S1).
3.10 Weight and Breadth of Evidence
for Biosimilarity
Regulatory authorities (e.g., FDA) base their final deter-
mination of biosimilarity between the proposed biosimilar
and the originator on the totality of the data submitted by
the biosimilar manufacturer for consideration. The authors
of this review did not attempt to assess the agents against
the criteria used by regulatory authorities, but instead based
their analysis on the totality of evidence in the public
domain with biosimilarity determined on the basis of
investigators’ conclusions.
In this analysis, the total number of studied variables
(from identified analytical/nonclinical studies) and total
reported patient numbers (from clinical studies) were
extracted and then mapped (Fig. 6a, b) against the ‘degree
of similarity’ (as observed by the study investigator). This
was to demonstrate the depth of the research programs and
the relative weight of supporting evidence available for
each agent. The number of studied variables and the
number of patients enrolled was not a factor in the deter-
mination of biosimilarity.
Molecules were mapped on a grid to illustrate relative
positioning. For the x-axis, the degree of similarity was
ranked using the investigator assessment of individual
clinical (Fig. 6a), analytical and nonclinical variables
(Fig. 6b). As an example, for PF-05280014, a proposed
biosimilar for trastuzumab, analytical and nonclinical data
were reported by investigators to be either similar or
identical (i.e., superimposable) across all variables asses-
sed. The positioning of PF-05280014 on the grid reflects
this. In contrast, Flores-Ortiz et al. [90], noted the mass
spectrometry and cation exchange data were heterogeneous
for the intended copy Kikuzubam in comparison with its
rituximab originator, while other variables (differential
scanning calorimetry analysis, peptide mapping, glycan
quantification, etc.) were reported to be the same. Thus, the
positioning of Kikuzubam was determined to be both
dissimilar and identical across selected variables.
Kikuzubam is the only molecule in this review that
exhibited such heterogeneity.
Based on clinical reports (Fig. 6a), development candi-
dates FTMB, RTXM83, and HD203 were reported to be
similar to their originators. Intended copy Yisaipu was
also considered by investigators to be similar. On the basis
of clinical studies, investigators found all other develop-
ment candidates and intended copies to be highly similar.
Investigators deemed a few molecules not to have met
biosimilarity criteria, at the time of reporting. Based on
preclinical reports (Fig. 6b), development candidate ABP
501 was determined to be dissimilar with respect to car-
bohydrate structure. Intended copies RedituxTM and
Kikuzubam (refer to Fig. 6 footnote) were also reported
to be dissimilar on the basis of a number of analytical and
nonclinical variables.
The body of evidence for biosimilar use in human
subjects from clinical studies is growing, with a high pro-
portion reporting patient samples of more than 100. Seven
proposed biosimilars have published clinical data on fewer
than 100 human subjects (namely BCD-020, BCD-022,
LBEC0101, SAIT101, ENIA11, RTXM83, and clotinab),
while CT-P13 and PF-05280014 have published studies
involving more than 1000 human subjects (which for
PF-05280014, includes patients from two published study
protocols, with an estimated pooled enrollment of
N = 910) (Fig. 6a).
When considering the breadth of data available for
preclinical studies for named biosimilars (based on number
of variables reported from structural, functional, and non-
clinical studies), the amount of reported information
available across studies was inconsistent (Fig. 6b). More
investigated variables for analytical and nonclinical
biosimilarity (ranging from 29 to 54) were published for
PF-05280586, PF-05280014, and GP2013. The remaining
agents published an average of only five variables across
their preclinical programs, as reported in the literature.
Although the investigators concluded that the majority of
molecules exhibited biosimilarity to their originator, it is
worth noting that comparative data were not provided for
all attributes studied.
3.11 Non-Empirical Publication Classifications
for Originators or Named Biosimilars
A significant number of non-empirical biosimilar publica-
tions on topics concerning ‘development and production’,
‘market analysis and uptake’, ‘regulation and safety’, or
general ‘overview’ review articles referenced originators
without citing named biosimilars (Table 4). The majority
of non-empirical publications cited originators for chronic
inflammatory diseases without reference to named
biosimilars (Table 4).
Publications focusing on development and production
were mainly concerned with biosimilar development,
manufacturing or supply processes, or quality and analyt-
ical methods. Publications categorized under ‘market
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Fig. 6 Biosimilarity and a total treated patients for named biosim-
ilars in clinical trials, b breadth of data for named biosimilars in
analytical and nonclinical studies. ‘Degree of similarity’ for biosim-
ilars and intended copies is inferred from the totality of evidence
provided from all available published studies (up to 3 September
2015) and is based on the original conclusions made by the study
investigators. The scale of reference used by each investigator was not
accounted for, as not uniformly reported. *Agents that have already
met the European Medicines Agency and/or US FDA requirements
and have been approved as biosimilars. Based on author interpre-
tation of study data, Kikuzubam purportedly exhibits some highly
dissimilar and some identical physicochemical characteristics com-
pared with the originator. PF-05280014 had two published study
protocols at the time of analysis with a combined enrollment of
N = 910 and a published study in 105 healthy subjects. ABX
abciximab, ADA adalimumab, BEV bevacizumab, ETN etanercept, IC
intended copy, INF infliximab, RTX rituximab, TRA trastuzumab


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































508 I. Jacobs et al.
analysis or uptake’ were mostly guidelines or reviews on
terminology and naming. The majority of non-empirical
overview publications were therapy area review articles or
systematic literature reviews. Publications on regulation
and safety aspects (either regulatory/policy or safety/
pharmacovigilance) were mostly identified for etanercept
and infliximab without reference to any named biosimilars.
The majority of non-empirical publications naming
biosimilars referenced CT-P13, which also appeared most
frequently in empirical publications. Other proposed
biosimilars featuring in a single non-empirical publication
included ENIA11, HD203, PF582, and GP2013.
3.12 Publishing Trends on Biosimilars
3.12.1 Journals
A total of 110 unique journal publications publishing rel-
evant material on mAb and fusion protein biosimilars were
identified between 2002 and September 2015. The journal
mAbs published the most articles on biosimilars, with 19
different articles since 2008, five of which were published
in 2015 (ESM Table S4). In September 2011, the journal
Biologicals published seven articles in a special issue
entitled ‘Evaluation of Similar Biotherapeutic products:
Scientific and Regulatory Challenges’ [91], which focused
on the key global health authorities in the evolving regu-
latory considerations and approval pathways for biosimi-
lars. This issue accounted for nearly half of the sharp rise in
publications in a single year, to a total of 19. The number
of publications dropped slightly in 2012 (n = 15), before
rising again to 17 and 18 publications in 2013 and 2014,
respectively. In 2014, the most articles were published by
the journals mAbs (n = 4), Annals of Rheumatic Diseases
(n = 3), Bioanalysis (n = 3), and BioDrugs (n = 3).
Between January and September 2015, nine publications
relevant to the topic of mAb or fusion protein biosimilars
were identified, the majority (n = 5) in mAbs.
3.12.2 Congresses
Proceedings from 17 conferences were searched and 192
congress abstracts publishing on biosimilar-relevant topics
were identified between 2009 and August 2015.
The top three identified congresses (in order of most
abstracts identified between 2009 and August 2015) were
European League Against Rheumatism (EULAR)
(n = 48), International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) (n = 33), and American
Association of Pharmaceutical Scientists (AAPS) National
Biotechnology Conference (n = 24) (ESM Table S5).
These congresses reflect the diversity of venues at which
biosimilars have been presented: disease specific
(immunology), outcomes research and payer-focused, and
manufacturing. Since 2012, the number of relevant abstract
publications has steadily risen from 14 in 2012 to 73 in
2014. In 2015 (up to the analysis cut-off date), 59 abstracts
were published on the topic of biosimilars, with the
majority (22 abstracts) appearing at the annual EULAR
congress and 11 at ECCO.
4 Discussion
Although an increasing number and broader range of
biosimilars are under development, and recently, the
world’s first mAb biosimilar was approved under the rigors
of the approval process of both the EMA and the FDA,
many clinicians still exercise caution over the use of
biosimilar products [92, 93]. Findings from the 2015
Coalition of State Rheumatology Organizations (CSRO)
survey suggested that, at the time, there were shared con-
cerns over the biosimilar approval process and unaddressed
critical issues, including the requirement for clearer guid-
ance from the FDA on interchangeability and naming,
which were considered important to address before new
biosimilar products arrived onto the market [93]. In a US
Alliance for Safe Biologic Medicines (ASBM) survey
conducted in 2015 [94, 95], 79% of physicians considered
that a definition of ‘biosimilarity’ was important/very
important for label inclusion. Over 80% of respondents felt
it was important to include analytical and clinical data to
demonstrate biosimilarity to the reference product; 79%
regarded the availability of post-marketing data in the
biosimilar label as important. As yet, there is no interna-
tional harmonized approach to the labeling of biosimilars.
The FDA has released draft guidance on labeling of
biosimilar products [84, 96]. The draft guidance includes
the addition of a ‘biosimilarity statement’ that is intended
to describe the biosimilar’s relationship with the reference
product [17, 96]. While biosimilar product-specific data are
regarded as ‘‘necessary to inform safe and effective use of
the product,’’ the FDA’s stance on inclusion of compara-
tive data in the label is that this may cause confusion
among healthcare providers and is not considered particu-
larly ‘‘relevant to a health care provider’s prescribing
considerations’’ [17]. The draft guidance is currently issued
for comment only, and the FDA will seek to incorporate
feedback from the public and industry before releasing the
finalized guidance. Under EMA guidelines, clinical and
preclinical data of the biosimilar are included in the
European Public Assessment Report (EPAR), with no
requirement to include comparative data on the biosimilar
product in the label. Furthermore, there is no citation of the
EPAR data in the label. Physicians may, therefore, not be
aware of how to access these data and incorrectly assume
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that all information on the biosimilar product is included in
the label [97]. Findings from a European survey in seven
countries revealed that 90.5% of physicians use the label
frequently or occasionally as an information source and
87.2% felt that a clear statement on the origin of the data
would be helpful [98]. Efficacy and safety considerations
notwithstanding, clinicians are becoming increasingly
receptive to prescribing biosimilars [99]. Certainly, further
clarity around biosimilar labeling will guide clinicians
toward making more informed prescribing decisions,
which may encourage the effective and appropriate use of
these agents in daily clinical practice.
During the course of this research it became evident that
a range of umbrella terms for biosimilarity has been
adopted to describe different attributes of molecules under
development, and in some cases applied to products that
have not undergone rigorous similarity exercises, as
required by the regulatory bodies (meaning they would be
more correctly named ‘intended copies’, or ‘non-compa-
rable biologics’) [1, 22, 23]. Thus, the published data
available on these products are insufficient to provide
robust evidence on their structural/functional similarity and
clinical efficacy and safety compared with the originator
product [24].
With this in mind, increased efforts should be made to
educate healthcare providers and other key stakeholders
responsible for the introduction and assimilation of
biosimilars into healthcare practice on the major distinction
not only between biosimilars of reference biologics and
generics of small molecules but also between biosimilars
and intended copies or biobetters. As an illustration, across
several emerging markets (including Mexico, Columbia,
and India), intended copies of biologics are marketed as
‘biosimilars’ without any published analytical similarity
data or robust clinical trials or based on evidence from
potentially flawed studies [1, 97, 100, 101]. Noteworthy
adverse events (grade 3/4) following administration of
intended copies of etanercept (Yisaipu or Infinitam) and
rituximab (Kikuzubam) have been reported in Mexico
and Columbia [66] along with claims of therapeutic failure
[1], which further serves to reinforce the importance of
maintaining a clear differentiation between these products
and biosimilars approved under the scientific and clinical
rigors of similarity assessment, as outlined by regulatory
agencies, to ensure the biosimilar drug efficacy and safety
are equivalent to those of the originator. Approval of
intended copies with limited or non-comparable data may
not only jeopardize patient safety but also create potential
confusion amongst healthcare stakeholders, especially as
these products co-exist on the market with biosimilars
while not conforming to the rigorous regulatory standards
set by the World Health Organization (WHO) [97] and
leading regulatory health agencies such as the EMA and
FDA. A further distinction must be made between
biosimilars and ‘next-generation biologics’ or ‘biobetters’,
which seek to outperform the originator molecules. Since
biobetters have been structurally engineered to improve
their clinical performance (including improved potency,
extended half-life, or reduced adverse events) [1], they are
not biosimilars and they must be differentiated on account
of structural differences and altered clinical behavior
[1, 22, 102].
Although immunogenicity is a key safety concern for
any biologic (i.e., for both originators and biosimilars), the
potential for it to arise during biosimilar production as a
result of small or undetectable differences between the
originator product and the biosimilar [103] presents a
unique challenge for biosimilar developers and regulatory
agencies. This is of particular importance for mAb and
fusion protein biosimilars because of their large molecular
size, complex protein structure, and post-translational
modifications [103].
At the time of marketing authorization or approval
application, pharmacovigilance and risk-management
activities for the post-authorization phase are recom-
mended by the FDA, EMA, and in accordance with the
WHO regulations to provide additional data on the safety
and efficacy of the biosimilar [104–108]; however, only
EMA guidelines specifically address immunogenicity dur-
ing post-approval surveillance monitoring. Furthermore, as
is the case for all medicines, side effects relating to use in
daily clinical practice, including off-label use or drug
interactions, will only be identified if biosimilar products
are continually traced and monitored in post-marketing
studies [109, 110]. During the course of our research into
biosimilars and intended copies, the majority of clinical
studies reported only limited data on immunogenicity
versus the originator.
Extrapolation of indications is particularly important for
mAb or fusion protein biosimilar products whose reference
agents are licensed for multiple indications [97, 111]. Both
the FDA and the EMA permit the extrapolation of
biosimilars [97], based on the totality of evidence provided
from clinical and nonclinical data, as well as taking into
consideration the proposed mechanism of action of the
product [111, 112]. Thus, biosimilar manufacturers need
only supply a sufficient degree of evidence to demonstrate
biosimilarity, without any requirement to provide clinical
trial data for all indications [13, 97, 104]. Indication
extrapolation remains an area of uncertainty, with regula-
tory decisions made on a case-by-case basis, and no ‘one-
size-fits-all’ approach.
As identified in this review, rituximab has a large
number of proposed biosimilars under development, both
for chronic inflammatory disease and oncology indications.
In oncology, biosimilars for trastuzumab, followed by
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bevacizumab, are leading the way; in chronic inflamma-
tory disease, etanercept and infliximab have the most
biosimilars as well as the largest volume of published
data, particularly for Celltrion’s EMA- and FDA-ap-
proved biosimilar CT-P13. Almost without exception,
studies we reviewed focused on mainly RA (for chronic
inflammatory disease), non-squamous non-small-cell lung
cancer, non-Hodgkin’s lymphoma, and HER2-positive
breast cancer (for oncology). At the time of review, no
published data for biosimilars in chronic inflammatory
diseases were available for psoriasis, psoriatic arthritis,
juvenile idiopathic arthritis, Crohn’s disease/ulcerative
colitis (with the exception of CT-P13), or ankylosing
spondylitis (excluding CT-P13). In oncology, among
biosimilars of bevacizumab, no published data were
available for colorectal cancer, cervical cancer, HER2-
negative breast cancer, renal cell carcinoma, or recurrent
glioblastoma multiforme. Within oncology indications for
rituximab biosimilars, no published data were retrieved
for chronic lymphocytic leukemia. Development in dis-
ease areas outside of oncology and chronic inflammatory
disease was less active; only three biosimilars were
identified with published data and only two molecules
with published empirical data.
Until recently, information comparing biosimilars with
their originator product has been limited outside of clinical
trials required for biosimilar approval; even less informa-
tion exists comparing biosimilars of the same reference
molecule. In this review, the majority of studies compared
biosimilars with their originators. However, due to the
widespread use of biologic disease-modifying antirheu-
matic drug therapy (and availability of intended copies on
the market), along with the development and approval of
an increasing number of biosimilar agents for chronic
inflammatory conditions, research efforts are now turning
towards comparisons with products of a different biological
class. Assuming all data are made public, this may be of
direct benefit to healthcare stakeholders and patients to
improve their understanding of how biosimilars compare
not only to their reference molecule but also to biologic
originators and approved or proposed biosimilars.
The growing number of marketed biosimilar agents
available, and increased volume of published clinical data,
presents future opportunities to develop post-marketing
comparative observational analyses or indirect treatment
comparisons, which may also be of benefit to regulatory
and healthcare stakeholders to better inform decision
making. Despite the existence of a relatively significant
amount of analytical, nonclinical, and clinical data, as
identified in this study, the majority are published as
abstracts in conference proceedings. Further studies pub-
lished in full text are required to reliably communicate
biosimilarity between originators and biosimilars, and the
completion of ongoing clinical trials in a variety of
biosimilar candidates is expected soon.
This study has provided information on the range of
mAb and fusion protein biosimilars available or in various
stages of development and the available scientific data
comparing them with their originator. CT-P13 and PF-
05280014 had the greatest evidence of similarity to their
originators on the basis of results from clinical studies
involving larger numbers of patients compared with other
named biosimilars for which the body of evidence is still
growing.
Strong evidence of similarity provided from analytical,
PK, and nonclinical studies is as essential as clinical evi-
dence in establishing the safety and efficacy of a biosimilar
and in meeting regulatory standards and requirements set
by the EMA and FDA for approval [104, 108]. Irrespective
of therapy area, this analysis also revealed that a significant
number of candidate products had no published evidence
(to date) of structural and functional comparability with
their originators from preclinical studies. This is true
among biosimilars of bevacizumab, trastuzumab, adali-
mumab, infliximab, rituximab, and etanercept. Not only are
these assessments important from a regulatory standpoint
for approval, but release of these data in the public domain
is also necessary for gaining acceptance among prescribers,
payers, and patients and to ensure sustainable market
uptake.
Several limitations of the study should be noted.
Although the search strategy was designed to capture a
relevant set of records, the database searches may not have
captured all terms related to therapy area or mAbs or fusion
protein biosimilars. Another limitation was that only pro-
ceedings from 17 conferences were searched, and although
consideration was given to identifying the most likely
venues for dissemination of relevant biosimilar research,
data may be available from other conference proceedings
not considered in this analysis. Owing to a lack of differ-
entiation in the published literature between biosimilars
and intended copies or biobetters, molecules may have
been labeled as biosimilars without rigorous data to support
biosimilarity, which could not be verified from this anal-
ysis. Several publications were retrieved with published
data on biosimilar molecules and referenced without a
distinguishable name. However, only data from publica-
tions disclosing names of biosimilars were extracted. The
final search result from each database was also limited to
reference records published in the English language. The
search for ongoing, planned, or complete clinical trials was
conducted using the ClinicalTrials.gov results database; no
other clinical trial registries were used in this analysis.
Therefore, it is possible that some trials (particularly those
being conducted outside of the USA) may not have been
captured. The registration and dissemination of trial data
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(including updates to protocols) on the ClinicalTrials.gov
site is at the full discretion of the study investigator or
sponsor and it is possible that some of the captured trial
information may be either out of date or inaccurate.
In this analysis, all studies were included regardless of
the risk of bias scores. For simplicity, conclusions on
biosimilarity were collectively drawn from a variety of
clinical study types (e.g., RCTs and observational
[prospective or retrospective] studies), without accounting
for any variation in the overall quality of evidence provided
by each study type. The determination of biosimilarity was
based on the specific term(s) chosen by the investigators in
formulating their conclusions. Therefore the determination
of, for example, ‘similar’ versus ‘highly similar’ was based
on the scale of reference used by each investigator.
Country of origin analyses were also not conducted on the
retrieved clinical data. This may present some information
bias, owing to varying standards between countries in
reporting trial data. In addition, biosimilars may have been
evaluated in different patient sub-populations (e.g.,
DMARD-naı¨ve vs. DMARD-IR [inadequate response]
patients); therefore, it may not be possible to draw ade-
quate conclusions on biosimilarity. Note also that when this
analysis was conducted, limited data were available for
analytical studies, and overall there was an inconsistency in
the data reported across studies of the same designated
category, limiting the extent to which conclusions could be
drawn. The determination of ‘proposed biosimilar’ versus
‘intended copy’ is limited in this analysis by uncertainty
surrounding the intentions of manufacturers with devel-
opment candidates. Therefore, the assumption that all
development stage molecules are ‘proposed biosimilars’
may not be accurate. Lastly, as this review represents a
cross-sectional analysis of available published evidence
over a defined period of time, the authors acknowledge the
molecules reviewed are at different stages of development,
and thus cannot be compared like-for-like. Since comple-
tion of this review, several biosimilars have new published
data across study types and several have transitioned into
their next stages of development.
Furthermore, new biosimilars in development (which
were not captured in this analysis) have since entered the
arena. For example, for chronic inflammatory diseases,
comparative safety/efficacy trials have since been listed in
the ClinicalTrials.gov registry for M923 (adalimumab;
Baxalta; psoriasis, RA) and MYL-1401A (adalimumab;
Mylan; psoriasis, psoriatic arthritis). In oncology, com-
parative safety/efficacy trials were recently documented for
ABP798 (rituximab; Amgen; non-Hodgkin’s lymphoma)
and for HLX01 (rituximab; Shanghai Henlius Biotech;
CD20 ? diffuse large B-cell lymphoma). In other disease
areas, a comparative safety/efficacy trial was identified in
the update search for FYB201 (ranibizumab; Bioeq GmbH;
age-related macular degeneration). It is important there-
fore, to acknowledge that this systematic review provides
only a cross-sectional analysis of biosimilar development
activities at the time the analysis was undertaken. The
authors may consider performing an update on this sys-
tematic review in the future.
5 Conclusions
The launch of biosimilars is expected to provide cost
savings and offers the potential to expand patient access to
important biologic medicines. At the time of writing, two
mAb biosimilars and one fusion protein biosimilar were
approved for use in the EU or USA and two further
molecules had received recommendations for approval in
the USA. However, recent surveys have revealed that some
confusion remains surrounding regulatory requirements,
labeling, and naming conventions for biosimilars. Addi-
tional knowledge gaps also exist for many clinicians and
other stakeholders around indication extrapolation.
With this in mind, this systematic review collated and
synthesized publically available information from the sci-
entific literature and conference proceedings on biosimilars
on the market and in development. The analysis high-
lighted progress on many fronts to harmonize and clarify
regulations and demonstrated the growing evidence base
available for biosimilar molecules. While the authors’
findings in this regard are reassuring, the analysis also
exposed significant differences in the extent of published
evidence between molecules at preclinical, clinical, and
post-marketing stages of development, something that is
particularly true for intended copies.
Concerted efforts by manufacturers and investigators to
disseminate available data and address gaps in the literature
together with further education and awareness among all
key stakeholders will be required to instill confidence and
trust in the safety and efficacy of biosimilar medicines,
thereby helping to support their use for the benefit of
patients.
An update of this SLR in the future may serve to con-
solidate more recent data and further highlight remaining
gaps in the published literature.
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